利拉鲁肽对 2 型糖尿病患者血糖控制和体重的影响：一项真实世界、观察性研究和简要叙述性综述。
Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review.
机构信息
Pharmaceutical Care Department, Ministry of the National Guard-Health Affairs, Dammam, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Department of Biostatistics and Bioinformatics, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
出版信息
Diabetes Res Clin Pract. 2021 Jul;177:108871. doi: 10.1016/j.diabres.2021.108871. Epub 2021 May 28.
BACKGROUND
Glycemic control and weight gain are two essential considerations in the pharmacological management of type 2 diabetes mellitus. Pharmacological agents are effective in lowering blood glucose levels but may result in significant weight gain. Liraglutideeffectively maintains glycemic control while reducingweight.
METHODS
This is a real-world study and brief narrative review of the effects of liraglutide on glycemic control and weight in adult patients with type 2 diabetes mellitus. The study uses data extracted from the electronic health record of the Ministry of National Guard-Health Affairs.
RESULTS
In this study of 348 subjects, there was a statistically significant reduction in hemoglobin A1c of 0.9% (P < .0001) and weight of 2.3 kg (P < .0001). The majority (77.3%) were on concomitant insulin.Subjects with a baseline hemoglobin A1c greater than 9% had a significantly greater reduction than those below 9% (-0.7%;P < .0001). Those with a weight more than 100 kg had a significantly greater reduction than those below 100 kg (-0.9 kg;P = .0096).
CONCLUSION
In this real-world, observational study, liraglutide was shown to be effective in improving glycemic control and reducing weight in adult patients with type 2 diabetes mellitus.
背景
血糖控制和体重增加是 2 型糖尿病药物治疗的两个重要考虑因素。药物治疗在降低血糖水平方面有效，但可能导致显著的体重增加。利拉鲁肽在有效控制血糖的同时减轻体重。
方法
这是一项真实世界的研究，并对利拉鲁肽对 2 型糖尿病成年患者的血糖控制和体重的影响进行了简要的叙述性综述。该研究使用了从国民警卫队卫生部电子健康记录中提取的数据。
结果
在这项对 348 名受试者的研究中，血红蛋白 A1c 显著降低了 0.9%（P<.0001），体重减轻了 2.3 公斤（P<.0001）。大多数（77.3%）同时使用胰岛素。基线血红蛋白 A1c 大于 9%的受试者比低于 9%的受试者有更大的降幅（-0.7%；P<.0001）。体重超过 100 公斤的受试者比体重低于 100 公斤的受试者体重减轻幅度更大（-0.9 公斤；P=.0096）。
结论
在这项真实世界的观察性研究中，利拉鲁肽被证明在改善 2 型糖尿病成年患者的血糖控制和减轻体重方面是有效的。
Zotero 插件